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ABSTRACT: Genetic discoveries in amyotrophic lateral
sclerosis (ALS) have a significant impact on decipher-
ing molecular mechanisms of motor neuron degeneration
but, despite recent advances, the etiology of most spo-
radic cases remains elusive. Several cellular mechanisms
contribute to the motor neuron degeneration in ALS, in-
cluding RNA metabolism, cellular interactions between
neurons and nonneuronal cells, and seeding of misfolded
protein with prion-like propagation. In this scenario, the
importance of protein turnover and degradation in motor
neuron homeostasis gained increased recognition. In this
study, we evaluated the role of the candidate gene HSPB1,
a molecular chaperone involved in several proteome-
maintenance functions. In a cohort of 247 unrelated Ital-
ian ALS patients, we identified two variants (c.570G>C,
p.Gln190His and c.610dupG, p.Ala204Glyfs∗6). Func-
tional characterization of the p.Ala204Glyfs∗6 demon-
strated that the mutant protein alters HSPB1 dynamic
equilibrium, sequestering the wild-type protein in a stable
dimer and resulting in a loss of chaperone-like activity.
Our results underline the relevance of identifying rare but
pathogenic variations in sporadic neurodegenerative dis-
eases, suggesting a possible correlation between specific
pathomechanisms linked to HSPB1 mutations and the as-
sociated neurological phenotype. Our study provides ad-
ditional lines of evidence to support the involvement of
HSPB1 in the pathogenesis of sporadic ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal, adult onset neurode-
generative disorder characterized by the progressive loss of upper
and lower motor neurons. The disease is mainly sporadic (sALS),
but 5–10% of patients have a positive family history (fALS). Starting
from the hypothesis of a sporadic disorder as the result of complex
genome–environment interactions, the inheritability of sALS has
been largely demonstrated in recent years. Although significant ad-
vances have been made in the molecular genetics of ALS, the screen-
ing of the currently known large- or small-effect genes only solves
a small fraction of sporadic cases and the etiology of sALS remains
mostly unexplained [Finsterer and Burgunder, 2014].
In this study, we evaluated the involvement of the small heat-
shock protein family B member 1 (HSPB1) (MIM#602195) in the
pathogenesis of ALS. The HSPB1 gene encodes an inducible molec-
ular chaperone able to reduce the aggregation of misfolded proteins
[Haslbeck et al., 2015]. HSPB1 has been found to be upregulated in
ALS mouse models [Vleminckx et al., 2002], as well as in the lum-
bar spinal cord specimens of ALS patients [Anagnostou et al., 2010].
In addition, mutations in this gene result in autosomal dominant
or recessive axonal peripheral neuropathies (distal hereditary mo-
tor neuropathy [dHMN] and Charcot-Marie-Tooth [CMT] type
2F), highlighting its relevance in maintaining neuronal integrity
[Evgrafov et al., 2004; Houlden et al., 2008]. Here, we report the
identification of two patient-specific HSPB1 mutations in two spo-
radic Italian ALS patients, additionally confirming its possible role
in the pathogenesis of this disorder.
Materials and Methods
Cohort Enrolment and Genetic Studies
The selected cohort was composed of 247 unrelated Italian pa-
tients presenting a clinical diagnosis of ALS. A first group of patients
(n = 153) has been enrolled in frame of the multicenter-multisource
prospective population-based registry “Liguria Amyotrophic Lateral
Sclerosis Registry” [Bandettini di Poggio et al., 2013] and through
the collaboration of other Italian centers. The second group of
patients (n = 94) has been enrolled at the Turin ALS center.
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Patients underwent neurological examination and were diagnosed
according to the El-Escorial revised criteria [Brooks et al., 2000].
The description of the enrolled cohort is provided in Supp. Table
S1. Informed consent was obtained from all participants and the
study was approved by the local ethics committee. The cohort was
selected based on the exclusion of pathogenetic variants in the major
genes associated with ALS pathogenesis (SOD1, TARDBP, FUS, and
C9orf72).
The coding regions of HSPB1 (Ensembl reference sequence:
ENST00000248553) was analyzed by direct sequencing (n = 153)
or denaturing high-performance liquid chromatography (DHPLC)
(Wave MD–Transgenomics, New Haven, CT, USA), followed by
Sanger sequencing of the variant chromatograms (n = 94). The SNP
rs545738637 T>C previously identified in HSPB1 promoter [Dierick
et al., 2007] was tested by direct sequencing at the genomic position
7:76302496 (GRCh38). Sequencing products were run on a 3130xl
Genetic Analyzer (Applied Biosystems–Thermofisher, Waltham,
MA, USA) and analyzed with SeqScape Software v.2.7 (Applied
Biosystems–Thermofisher, Waltham, MA, USA). For cDNA num-
bering, nucleotide numbering uses +1 as the A of the ATG translation
initiation codon in the reference sequence, with the initiation codon
as codon 1. The ethnically matched control cohort (n = 250) was
analyzed by DHPLC (Wave MD–Transgenomics, New Haven, CT,
USA). Whole-exome sequencing of patient ALS-160 was performed
by deCODE Genetics, Iceland. Exome enrichment was performed
using Nextera and run on HiSeq2500 (Illumina, San Diego, CA,
USA). Reads alignment and variants calling was performed with
BWA and GATK software. The methods used for the functional
studies are detailed in the Supporting Information Material.
Molecular Modeling
Up to now, various crystallographic data of human heat-shock
proteins (HSPs) have been obtained and released on protein data
bank, one of the latest being human HSPB1 α-crystallin domain
(ACD; 84–176 residues) (pdb code: 4MJH; resolution = 2.60 Å)
[Hochberg et al., 2014]. Since small HSPs share a highly conserved
ACD, a whole human B1 theoretical model was performed by ho-
mology modeling techniques, on the basis of a multiple template
alignment strategy focused on the X-ray data of the available HSPs,
as recently published [Fossa and Cichero 2015]. The HSPB1 mu-
tant models were obtained by the residue rotamer explorer imple-
mented in the MOE sequence editor (Chemical Computing Group
Inc., Montreal, Canada), followed by residue minimization using
AMBER99 force field. Aggregation-prone regions in the three mod-
els were calculated using the Protein Patch Analyzer module imple-
mented in the MOE software.
Results
Genetic Findings
The molecular analysis of HSPB1 was performed in both the
patient (n = 247) and the control (n = 250) cohort. The ge-
netic screening revealed the presence of two patient-specific vari-
ations (c.570G>C, p.Gln190His and c.610dupG, p.Ala204Glyfs∗6;
variations submitted in http://www.lovd.nl/HSPB1), together with
additional synonymous variations (Fig. 1A).
The heterozygous missense mutation c.570G>C, p.Gln190His
(Fig. 1B, left) was identified in the sporadic ALS patient SLA2014-
469. The residue p.Gln190 is conserved among HSPB1 orthologous
(Fig. 1D) and in silico predictions using SIFT and Polyphen-2 show
the missense variant to be deleterious with the score of 0.00 and
0.974, respectively (see details under the Supporting Information
Material).
The heterozygous frameshift c.610dupG, p.Ala204Glyfs∗6
(Fig. 1B, right) was identified in the sALS patient ALS160. The gua-
nine duplication affects the third to last codon of HSPB1 and leads
to the translation of eight additional base pairs in the 3′UTR of the
gene, resulting in an extended mutant protein (Fig. 1C). The align-
ment of HSPB1 C-terminal domain across different species showed
the conservation of the p.Ala204 amino acid and none of the se-
lected HSPB1 orthologous displayed a similar C-terminal extension
(Fig. 1D).
The variants c.570G>C and c.610dupG were absent from public
databases for human variations (dbSNP138, 1000 Genomes, Exome
Variant Server and ExAc v.03) and were not identified in the se-
lected control cohort. Moreover, in order to exclude the association
of these variants with an inherited peripheral neuropathy pheno-
type, their presence was excluded by screening an additional 660
chromosomes of dHMN or CMT patients. The occurrence of other
possible pathogenic mutations in the patient ALS160 has been ex-
cluded by whole-exome sequencing, after filtering against the full
up-to-date list of ALS-associated genes. Interestingly, the promoter
variant rs545738637 T>C previous identified in a Belgian sALS pa-
tient was not identified in our cohort.
Clinical Description of the Patients Harboring HSPB1
Mutations
Case 1: SLA2014-469 (p.Gln190His). The patient SLA2014-469
developed dysphagia and dysarthria at the age of 58 years. Few
months later, she showed weakness and atrophy at the muscles of
the right hand. Neurophysiological examination showed active and
chronic denervation at upper and lower limbs and at genioglossus
muscle. Spirometry showed a marked restrictive pattern (FVC 56%)
and creatine kinase was increased. Neuropsychological examination
showed a mild cognitive impairment, mainly behavioral. Although
her family history was negative for ALS, her mother was referred
as affected by Alzheimer’s disease. She was diagnosed with definite
ALS and she died from respiratory failure, 24 months after the
onset.
Case 2: ALS160 (p.Ala204Glyfs∗6). The patient ALS160, with a
negative family history for neurological disorders, at the age of 73
developed balance disturbances with frequent falls and signs of ex-
trapyramidal involvement for which a diagnosis of possible multiple
system atrophy with cerebellar predominance was made. She arrived
at our attention at the age of 77 because of bulbar symptoms and
diffuse signs of spinal amyotrophy. She did not show any cerebellar
sign. The neurophysiological study showed axonal motor neuropa-
thy in lower limbs and signs of denervation and reinnervation at four
limbs and paravertebral muscles. A diagnosis of ALS-plus syndrome
with extrapyramidal features [McCluskey et al., 2014; Pupillo et al.,
2015] was made. At the age of 78, she developed scanning dysarthria,
mixed dysphagia, and respiratory insufficiency leading to noctur-
nal noninvasive ventilation. To date, at the age of 82, neurological
examination shows severe cranial involvement, diffuse hyposthenia
with muscular hypotrophy, fasciculation, and brisk deep tendon re-
flexes at four limbs. Hypomimia with resting, postural, and kinetic
tremor in both hand and head is also evident. Postural changes are
performed with assistance and the patient is wheelchair bounded.
Signs of cognitive impairment are not evident.
Functional Analysis
To better frame the implications of HSPB1 mutations in the
pathogenesis of ALS, we studied the functional effect of the
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Figure 1. Molecular analysis of HSPB1. The patient-specific, control-specific, and shared HSPB1 variations identified in this study are depicted
in red, blue, and green, respectively, on the schematic protein representation. The known HSPB1 functional domains (N-terminal motif WDPF, ACD:
alpha-crystallin domain, C-terminal domain IXI/V) and the three phosporylation sites (©P ) on p.Ser15, p.Ser78 and p.Ser82 are highlighted (panel
A). The electropherogram of the heterozygous missense mutation c.570G>C on genomic DNA is shown compared to a wild-type sequence (panel
B, right). The heterozygous frameshift c.610dupG is depicted with the corresponding nucleotide difference between wild-type and mutant allele in
the electropherogram data (panel B, left). The duplication of a guanine in position c.610 determines the translation of eight additional base pairs
in the 3′UTR of the gene, resulting in an extended protein (panel C). Multiple alignment of HSPB1 C-terminus in different orthologous shows the
conservation of the residue p.Gln190 and that none of the selected species presents with an additional C-terminal segment, as is the case for the
mutant p.Ala204Glyfs∗6 (panel D).
p.Ala204Glyfs∗6 mutation on patient-derived lymphoblastoid cell
lines (LCLs). Unfortunately, no patient-derived material was avail-
able for the mutant p.Gln190His.
HSPB1 expression and induction in ALS160
EBV-transformed LCLs
To explore the effect of the p.Ala204Glyfs∗6 mutant on cellu-
lar homeostasis, we first investigated whether it could impair the
HSPB1 expression level, using patient-derived LCLs, demonstrat-
ing that both wild-type and mutant alleles are expressed on mRNA
and protein level (Supp. Fig. S1A and B). On protein level, HSPB1
expression seemed to be noticeably reduced in the patient ALS160,
compared to controls (Supp. Fig. S1C), remarkably without trigger-
ing neither the proteasomal- nor the lysosomal-dependent degra-
dation pathways (Supp. Fig. S2).
Although it is expressed in basal conditions, HSPB1 is striking
upregulated upon cellular stress, a situation in which the concen-
tration of aggregation-prone folding intermediates increases and
this protein mainly exerts its chaperone and cytoprotective func-
tions [Oesterreich et al., 1996]. Through heat-shock experiments,
we demonstrated that HSPB1 is still inducible in patient-derived
LCLs (Fig. 2A). Together, these results suggest that there is no spe-
cific degradation or defect in the expression/induction of HSPB1
in ALS160 compared to controls. We therefore decided to evaluate
whether HSPB1 was still functional upon homeostasis perturbation.
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Figure 2. HSPB1 p.Ala204Glyfs∗6 sequesters the wild-type protein in a stable dimer impairing its chaperone-like activity. The upregulation of
HSPB1 in both control and patient LCLs upon heat shock (42°C) is depicted in panel (A). The untreated condition (NT) is compared to the heat-shock
condition without recovery (HS noR) and to different recovery time points, respectively, 2, 4, 6, 8, 12 and 24 hr (HS R2h to HS R24h). As a positive
control, the membranes were probed for heat-shock factor 1 (HSF1), known to be phosphorylated during heat-shock condition. The phosphorylation
results in the increase in its molecular weight as depicted in panel (A) lanes 3 and 4.To evaluate the molecular weight of the dimeric structures
observed in patient-derived LCLs, we compared this cell line with control LCLs and with three CHO-K1 stable cell lines expressing the constructs
encoding for HSPB1 wild-type, mutant or a combination of both (panel B). The naı̈ve CHO-K1 cell line does not express HSPB1, thus allowing
evaluating its dimerization in the absence of the endogenous protein. The dimer-monomer shuttling has been evaluated in patient-derived LCLs
compared to control (panel C). Basal conditions are compared to poststress conditions (HS R4h) in both nonreducing (nred) and reducing (red)
settings. The chaperone-like activity of HSPB1 p.Ala204Glyfs∗6 has been evaluated as its ability to clear SOD1 p.Ala4Val-GFP aggregates in double
stable CHO-K1 cell lines (panel D). The clearance of SOD1 aggregates determines a different solubility of the protein, reducing the signal in the
pellet fraction. HSPB1 wild-type (wt) is able to clear the SOD1 p.Ala4Val aggregates in double stable CHO-K1 cell lines as shown in lane 7. When
comparing the CHO-K1 lines expressing HSPB1 wt (lane 7) to the one expressing p.Ala204Glyfs∗6 (mut) (lane 8), we showed that the presence
of the mutation determines an increase in the GFP signal in the pellet fraction, suggesting that the mutant protein is not able to clear the SOD1
aggregates.
HSPB1 p.Ala204Glyfs∗6 sequesters the wild-type protein in a
stable dimer
Small HSPs exhibit a pronounced dynamic equilibrium be-
tween monomeric, dimeric, and oligomeric state. The oligomers
are believed to be reservoirs, which dissociate upon stress into
the active dimer and monomer forms. The HSPB1 dimer inter-
face is located within the alpha-crystallin domain and it is further
strengthened and stabilized by the C-terminus [Vos et al., 2008].
Therefore, we evaluated whether the additional C-terminal exten-
sion of the p.Ala204Glyfs∗6 mutation affected HSPB1 dimeriza-
tion by analyzing the protein migration pattern in nonreducing
conditions. In the presence of two different proteins, we expected
the formation of three dimer combinations (wild-type/wild-type,
wild-type/mutant, and mutant/mutant). Interestingly, the patient-
derived LCLs showed only one structure, with a higher molecu-
lar weight than controls. In order to better understand the mu-
tant HSPB1 dimerization properties and composition, we used
CHO-K1 cell lines, stably expressing HSPB1 wild-type, HSPB1
p.Ala204Glyfs∗6, or both. Intriguingly, while both the wild-type and
the mutant proteins are able to form homodimers, the double stable
CHO-K1 cell line confirmed the pattern observed in patient-derived
LCLs, showing only one dimer and apparently corresponding to the
wild-type/mutant dimer (Fig. 2B). These data suggest that when the
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two proteins are expressed together, the dimerization pattern shifts
predominantly to the wild-type/mutant form.
In the context of HSPB1 dynamic equilibrium, we previously
demonstrated that, during poststress recovery, the monomeric form
is upregulated and the dimers dissociates into monomers [Almeida-
Souza et al., 2010]. Interestingly, we demonstrated that, upon
heat-shock, in patient-derived LCLs, the increased expression of
monomeric HSPB1 was not associated with a dimer–monomer
shuttling (Fig. 2C). This result suggests that the wild-type/mutant
dimer forms a stable structure, not able to dissociate and therefore
perturbing the dynamic equilibrium of HSPB1.
To explain the different dimerization properties observed, we
evaluated the surface steric and electrostatic profile of the mutant
C-terminus extension, building a specific 3D model. In the native
HSPB1, molecular modeling data suggest that the dimers formation
is promoted by the exposure of a number of weak noncovalent
contacts sites in specific surface patches. While the wild-type HSPB1
displays a precise charge distribution across the C-terminal domain
(Supp. Fig. S3A), the mutant protein shows marked electrostatic
alterations (Supp. Fig. S3C), with a smaller highly hydrophobic
region, a reduced negative charge area and an additional positive
patch resulting from the mutated residues 204–208 (Supp. Table
S2). Interestingly, the 3D model of the p.Gln190His revealed a clear
modification of the hydrophilic properties compared with the wild-
type protein (Supp. Fig. S3B), leading to a much more extended
positive surface at the C-terminal domain (Supp. Table S2).
Taken together, these data suggest that the difference between na-
tive and mutant p.Ala204Glyfs∗6 HSPB1 dimerization kinetics can
be partially explained by different hydrophobic and polar contacts
at the protein surface. In addition, while both the p.Gln190His and
the p.Ala204Glyfs∗6 mutations affect the charge distribution of the
C-terminal domain, the p.Gln190His seems to be much more prone
to aggregation rather than the p.Ala204Glyfs∗6, displaying overall
acceptable hydrophobic patches if compared with the native protein.
However, additional functional studies are needed to confirm this
hypothesis.
HSPB1 p.Ala204Glyfs∗6 results in a loss of chaperone-like
activity
Previous studies have shown that shuttling between monomers,
dimers and oligomers is required for the proper substrate bind-
ing and chaperone-like activity of HSPB1 [Giese and Vierling,
2002]. Nonnative substrates are maintained in a folding-competent
state, promoting their refolding or, when this is not possible, their
degradation [Hartl et al., 2011]. Based on the different dimer-
ization profile observed for HSPB1 p.Ala204Glyfs∗6, we investi-
gated whether this mutant HSPB1 still preserved its chaperone
activity. We therefore performed an indirect clearance assay us-
ing the aggregation prone superoxide dismutase 1 (SOD1) mutation
p.Ala4Val as a substrate. The formation of aggregates was quanti-
fied by separating the aggregates-containing pellet fraction from the
supernatant. As shown in Figure 2D, wild-type HSPB1 assists in
refolding/degradation of SOD1 p.Ala4Val, reducing the amount of
insoluble SOD1 p.Ala4Val in the pellet fraction. However, the pres-
ence of the HSPB1 p.Ala204Glyfs∗6 increases the amount of SOD1
p.Ala4Val aggregates in the pellet fraction, when compared to the
wild-type HSPB1, suggesting that the mutant protein results in a
loss of chaperone-like activity.
Discussion
Several neurodegenerative disorders, as Huntington, Alzheimer,
Parkinson, and ALS, are characterized by the accumulation of
neuronal intracellular aggregates, which impairs neuronal connec-
tivity and triggers cell death signaling pathways. This accumulation
is caused by the incapacity of the molecular chaperones to over-
come the instable folding intermediates, leading to protein insolu-
bility and precipitation. To corroborate this hypothesis, it has been
shown that the overexpression of the chaperones HSP70 and HSP90
suppresses protein aggregation, hence influencing the neuronal phe-
notype [Muchowski, 2002]. Interestingly, mutated SOD1 aggregates
sequester a number of HSPs, including HSPB1 [Yerbury et al., 2013]
suggesting that, in pathological conditions, the availability of these
chaperones to undertake their housekeeping functions is drastically
reduced, impairing neuronal responses to cellular stress and result-
ing in an increased vulnerability [Kalmar et al., 2014].
In this report, we describe for the first time two HSPB1 coding
variants identified in two unrelated sALS patients. The molecular
analysis of the patient and the control cohort demonstrated that
nonsynonymous variations are patient specific, as we did not iden-
tify any but synonymous variants in the control population. In
addition, the incidence of frameshift variations identified in the
ALS cohort analyzed in this study exceeds in respect to the data
available in the ExAC database (ALS cohort: 0.405% vs. ExAC:
0.005%, P-value = 0.032; 95% CI, Fisher’s exact test, with Bon-
ferroni correction), while the incidence of the missense muta-
tions is similar in both datasets, showing no statistically signifi-
cant difference. The variants p.Gln190His and p.Ala204Glyfs∗6 are
both located in the C-terminal domain of HSPB1, a region in-
volved in the control of its chaperone-like activity [Lelj-Garolla and
Mauk, 2012]. The functional characterization of different periph-
eral neuropathies-related mutations, located in this domain, did
not show a clear correlation between the location of the mutant
and the associated cellular phenotype. While some mutations dis-
play an aggregation-prone tendency (e.g., p.Pro182Leu) [Evgrafov
et al., 2004], some other located in the same proximity do not
show any sign of aggregation (e.g., p.Thr180Ile) [Chalova et al.,
2014]. This indicates that the nature of the substitution, instead
of its location within the protein structure, determines the related
cellular consequences. The availability of patient-derived material
for the extended frame-shift p.Ala204Glyfs∗6 allowed us to analyze
the biochemical properties of this mutant, subsequently confirmed
with in vitro studies. We demonstrated that the mutant protein se-
questers the wild-type protein in a stable dimer, severely affecting
HSPB1 monomer–dimer dynamic equilibrium. Although no crystal
structure of the C-terminal part of HSPB1 has been deposited, the
homology model of the full structure of HSPB1 has been recently de-
scribed [Fossa and Cichero, 2015]. Using these coordinates, we were
able to model the p.Ala204Glyfs∗6 additional C-terminal extension.
We confirmed that the different dimerization kinetic displayed by
this mutant is sustained by an altered surface steric and electrostatic
protein profile across the C-terminal domain, impairing hydropho-
bic and polar contact points in this area. Supporting these data,
we demonstrated the p.Ala204Glyfs∗6 mutation results in a loss of
chaperone-like activity, being the mutant HSPB1 unable to clear
aggregating substrates. The HSPB1 gene is one of the most frequent
causes of dHMN and axonal CMT disease with predominant motor
involvement [Houlden et al., 2008; Capponi et al., 2011]. Func-
tional studies on some of the CMT-associated missense mutations
showed a gain of toxic function mechanism. The mutant proteins
displayed hyperactivity, caused by an increased monomerization of
HSPB1 and leading to the enhanced affinity to their client proteins
[Almeida-Souza et al., 2010]. In particular, these mutants showed
a strong binding to tubulin and microtubules, leading to the over-
stabilization of the microtubules network [Almeida-Souza et al.,
2011]. Recent studies on the C-terminal truncated p.Met169Cysfs∗2
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mutation demonstrated that this terminal part of HSPB1 is neces-
sary for cell survival upon misfolded protein-induced stress. The
truncated HSPB1 mutation exerted a dominant negative effect by
binding the HSPB1 wild-type decreasing the abundance of wild-type
dimers. Interestingly, with canavanine-induced protein aggregation,
fibroblasts heterozygous for the truncated p.Met169Cysfs∗2 mutant
displayed decreased cell viability [Ylikallio et al., 2015].
In this report, we show that the HSPB1 mutation p.Ala204Glyfs∗6
leads to a loss of chaperone-like activity. Intriguingly, the first report
of ALS-associated single nucleotide polymorphism (SNP) in HSPB1
suggested a similar feature. Dierick and collaborators previously
reported the SNP rs545738637 T>C in the HSPB1 promoter in a
Belgian sALS patient. This variant is located within the heat-shock
element (HSE), a consensus sequence for the specific binding of
the heat-shock factor 1 (HSF1). The binding of HSF1 on HSE is
essential for the upregulation of HSPB1 upon stress. The presence
of the SNP rs545738637 T>C leads to the impairment of HSPB1
stress-related increased transcription, thus resulting in a severely
affected heat-shock response [Dierick et al., 2007].
Taking these data and our findings together, it becomes tempt-
ing to speculate about a correlation between different pathomech-
anisms of HSPB1 mutations and the resulting neurodegenerative
phenotype. The CMT-associated HSPB1 mutations result in a hy-
peractive protein, enhancing the binding to their client proteins and
leading to downstream effects detrimental in peripheral neurons.
On the contrary, an impaired heat-shock response, either due to
the lack of HSPB1 upregulation during stress conditions or result-
ing from a loss of chaperone-like activity, might contribute to the
pathogenesis of ALS making the motor neurons more vulnerable
to homeostasis perturbation. It is well documented that the aging-
related accumulation of misfolded/oxidized proteins is a challenge
to the proteostasis system, in particular in long-living cells like mo-
tor neurons. This is due to the fact that the age-related decline
in the proteostasis machinery determines the inability to upregu-
late chaperones in response to conformational stress [Hartl et al.,
2011]. In this scenario, the presence of HSPB1 mutations would
trigger the disease manifestation, perturbing central proteostasis,
including folding and clearance mechanisms. Interestingly, the im-
pairment of protein degradation pathways have already been linked
to the pathogenesis of ALS through the identification of mutations
in the ubiquitin-like protein Ubiquilin2 (UBQLN2) [Deng et al.,
2011] and the autophagy-related Sequestosome 1 (SQSTM1) [Fecto
et al., 2011] in familial and isolated cases.
ALS is a complex disease and the interactions among several
genes influence its pathogenesis, providing a different effect on the
phenotypic presentation [Leblond et al., 2014]. In regard to the
complexity to decipher the genetic landscape of sALS, the investi-
gation of the cellular implications of rare but pathogenic mutations
can provide a novel approach to evaluate relevant molecular path-
ways in this sporadic disease. The investigation of the HSPB1 gene
in broader ALS/ALS-plus cohorts might therefore offer additional
insights into deciphering the molecular basis of this motor neuron
Disorder.
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